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Scope: The physiological relevance of contemporary cell culture studies is often 
perplexing, given the use of unmetabolized phytochemicals at supraphysiological 
concentrations. We investigated the activity of physiologically relevant anthocyanin 
metabolite signatures, derived from a previous pharmacokinetics study of 500 mg 
13C5-cyanidin-3-glucoside in 8 healthy participants, on soluble vascular adhesion 
molecule-1 (VCAM-1) and interleukin-6 (IL-6) in human endothelial cells. 
Methods and results: Signatures of peak metabolites (previously identified at 1, 6 
and 24 h post-bolus) were reproduced using pure standards and effects were 
investigated across concentrations ten-fold lower and higher than observed mean 
(<5 µM) serum levels. Tumor necrosis factor-α (TNF-α)-stimulated VCAM-1 was 
reduced in response to all treatments, with maximal effects observed for the 6 h and 
24 h profiles. Profiles tested at ten-fold below mean serum concentrations (0.19-0.44 
µM) remained active. IL-6 was reduced in response to 1, 6 and 24 h profiles, with 
maximal effects observed for 6 h and 24 h profiles at concentrations above 2 µM. 
Protein responses were reflected by reductions in VCAM-1 and IL-6 mRNA, however 
there was no effect on phosphorylated NFB-p65 expression.  
Conclusion. Signatures of anthocyanin metabolites following dietary consumption 
reduce VCAM-1 and IL-6 production, providing evidence of physiologically relevant 
biological activity. 
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Graphical abstract summary 
A novel approach to exploring the biological activity of flavonoid metabolites in vitro. We investigated 
the activity of anthocyanin metabolite signatures, identified in a previous pharmacokinetic study of 
13
C5-cyanidin-3-glucoside. Here, differing concentrations of metabolite signatures inhibited soluble 
vascular adhesion molecule-1 (VCAM-1) and interleukin-6 (IL-6) in human endothelial cells, providing 





The consumption of anthocyanins has been linked to a reduced risk of 
cardiovascular disease [1, 2], though their mechanisms of action are not fully 
understood. Traditionally, in vitro studies have explored the activity of parent 
anthocyanins mechanistically, however their low plasma concentrations and rapid 
clearance kinetics suggests they are not the bioactive forms responsible for in vivo 
activity. It is therefore probable that anthocyanin bioactivity in vivo results from the 
lesser studied, though more bioavailable, phenolic metabolites, and we have recently 
demonstrated they are more active on inflammatory biomarkers than their precursor 
structures [3-5]. 
The understanding of anthocyanin metabolism is relatively contemporary, though it is 
commonly accepted that their degradation is a result of their chemical instability and 
the impact of bacterial catabolism, resulting in a number of circulating phenolic 
metabolites [6, 7]. As anthocyanin metabolites do not circulate in isolation following 
ingestion, but exist as complex mixtures or profiles of metabolites at various 
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concentrations [8-10], it is important that this is also reflected in the design of 
experiments exploring the bioactivity of anthocyanins.  
The metabolism of a common dietary anthocyanin, cyanidin-3-glucoside (C3G), was 
recently investigated and 29 metabolites were identified following the consumption of 
500 mg 13C-labelled cyanidin-3-glucoside (C3G) [8, 11]. Briefly, eight healthy male 
participants were fed a single 500 mg oral bolus dose of isotopically labelled C3G 
(13C5-C3G) following a 7 day washout period (avoiding anthocyanin-rich foods),  
were blood was collected at baseline, 0.5, 1, 2, 4, 6, 24, 48 h. Three distinct peak 
serum metabolite profiles (or signatures) were observed post consumption at 1 h, 6 
h, and 24 h (Figure 1). Similar groupings of metabolites sharing Cmax and producing 
distinct biosignatures or peaks of metabolites during clearance have also been 
observed following consumption of cocoa flavan-3-ols [12] and citrus flavanones 
[13], suggesting this is a common response in the clearance  kinetics of flavonoid 
metabolites. Given that these phenolics circulate at higher concentrations and for 
longer duration relative to their precursor structures, there is scope to investigate the 
collective activity of blood profiles of phenolic metabolites on inflammatory 
processes. 
Anthocyanin metabolites have been shown to inhibit the expression of a number of 
inflammatory biomarkers, such as those involved in vascular adhesion and 
chemotaxis, including soluble vascular cellular adhesion molecule-1 (VCAM-1) and 
interleukin-6 (IL-6) [14, 15], both of which are markers of cardiovascular disease risk 
and mortality [16, 17] and logical targets for exploring the potential mechanisms of 
action of anthocyanin metabolites. The aims of the present  study were therefore: 
investigate the effects of unique C3G metabolite signatures, observed to peak in vivo 
at 1 h, 6 h, and 24 h post consumption, on VCAM-1 and IL-6 protein secretion by 2 
cell types, human umbilical vein endothelial cells (HUVEC) and human coronary 
artery endothelial cells (HCAECs); investigate the effects of metabolite signatures 
across a range of concentrations, reflecting levels ten-fold lower (<0.5 µM) and ten-
fold higher (<50 µM) than mean concentrations (<5 µM) observed previously [8, 11]; 
finally, identify mechanistic effects on VCAM-1 and IL-6 mRNA by targeting a key 
inflammatory transcriptional target, NFB. 
Methods 
Materials 
Early passage human umbilical vein endothelial cells (HUVECs) (cryopreserved, 
pooled donors, passage 2), large vessel endothelial growth medium (containing 2% 
fetal calf serum, human epidermal growth factor, human fibroblast growth factor, 25 
µg/mL gentamycin, 50 ng/mL amphotericin, hydrocortisone and heparin) and trypsin 
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passage pack were purchased from Caltag Medsystems (Buckingham, UK). Early 
passage (passage 2) human coronary artery endothelial cells (HCAECs) 
(cryopreserved, single donors), endothelial cell medium MV (containing 5% fetal calf 
serum, endothelial cell growth supplement, recombinant human epidermal growth 
factor, heparin, and hydrocortisone) and Detach Kit were purchased from PromoCell 
GmbH (Heidelberg, Germany). Human-derived fibronectin and TNF-α was 
purchased from Sigma Aldrich (Dorset, UK). The conjugated metabolites, as listed in 
Table 1, were synthesized at the University of St. Andrews (UK) [18]. Human-derived 
fibronectin, TNF-α, and all flavonoids and unconjugated phenolic acids (Table 1) 
were obtained from Sigma Aldrich (Dorset, UK), with the exception of cyanidin-3-
glucoside (Extrasynthase, France). 
Treatment metabolite profiles 
Stock solutions for cell culture experiments were prepared in 100% DMSO at 200 
mM and stored at -80oC with the exception of cyanidin-3-glucoside, which was 
prepared at 40 mM, and the sulfate- conjugated phenolic acids, which were prepared 
at 25 mM in 50% DMSO (50% PBS) to maintain stability whilst reducing final DMSO 
concentrations in working solutions. Working solutions of 1 mM were prepared in 
supplemented media before being diluted to their working concentrations (Table 1) 
and stored at 4oC until experimental commencement (with the exception of cyanidin-
3-glucoside, which was added immediately prior to the final dilutions to maintain 
stability). Solutions were subsequently diluted in supplemented media as required 
(Table 1) immediately prior to experiment commencementt.  
Cell culture  
HUVECs and HCAECs were routinely cultured in fibronectin coated T75 flasks (0.25 
µg/cm2), using large vessel endothelial growth medium and endothelial cell medium 
MV, respectively, at 37°C and 5% CO2. Cells were sub-cultured using a trypsin 
passage pack or Detach Kit, according to the manufacturer’s instructions. HUVECs 
were used at passage 4 and HCAECs were used between passages 3 and 6. All 
cells were incubated in supplemented media for 24 h at 37oC, 5% CO2, in a 
humidified atmosphere, prior to experiment commencement.  
VCAM-1 and IL-6 protein expression 
HUVEC or HCAEC were seeded at 80,000 cells/well in fibronectin coated 24-well 
plates. Cells were treated for 30 min with peak metabolites profiles identified 
previously at 1 h, 6 h, 24 h post consumption (Table 1) or 0.01% DMSO (vehicle 
control) prior to the addition of 10 ng/mL (HUVEC) or 0.1 ng/mL (HCAEC) TNF-α 
(determined as providing maximal induction while maintaining physiological relevant 
concentrations following time- and concentration-response experiments), and 
incubated for 24 h at 37oC, 5% CO2, in a humidified atmosphere.  Supernatants were 
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collected on ice, centrifuged at 2000 x g for 10 min at 4oC, and stored at -80oC prior 
to ELISA. Samples were thawed at room temperature and vortexed for 3 x 5 sec 
immediately prior to analysis. Supernatants were diluted 1:1 in Reagent Diluent 
(R&D Systems) and protein expression of soluble VCAM-1 (sVCAM-1; hereby 
referred to as VCAM-1) and IL-6 were determined by commercially available DuoSet 
enzyme-linked immunosorbent assay (ELISA) (R&D Systems), according to the 
manufacturer’s instructions. Absorbance values for all ELISA plates were recorded 
using an OMEGA plate reader from BMG LABTECH (Bucks, UK). 
VCAM-1 and IL-6 mRNA expression 
HCAEC were seeded at 200,000 cells/well in fibronectin coated 6-well plates. Cells 
were pre-treated for 30 min with the highest working concentrations of the metabolite 
profiles (19 µM, 20 µM, 44 µM, reflecting serum concentrations at 1 h, 6 h, 24 h 
respectively) of each serum profile or 0.01% DMSO (vehicle control) prior to the 
addition of 0.1 ng/mL TNF-α, and incubated for 4 h at 37oC, 5% CO2, in a humidified 
atmosphere. Cell culture supernatants were removed and cells washed 3 x with 
PBS. Total RNA was extracted from HUVECs and reverse transcribed to cDNA 
using conditions previously described [3].Real-time quantitative PCR (RT-qPCR) 
was carried out using 25 ng cDNA with the addition of VCAM-1 primers (forward 
primer, 5’-CAGGCTAAGTTACATATTGATGACAT-3’; reverse primer, 5’-
GAGGAAGGGCTGACCAAGAC-3’), or IL-6 primers (forward primer, 5’-
GCAGAAAACAACCTGAACCTT; reverse primer, 3’-
ACCTCAAACTCCAAAAGACCA-5’) and real time PCR Precision master mix with 
SYBR green (Primer Design, UK). RT-qPCR was carried out using the ABI7500 
(Applied Biosystems, UK) system, using cycle methods previously described [3]. 
Relative changes in gene expression from the TNF-α control were quantified using 
the comparative Ct method [19]. The difference between recorded Ct values for 
treatment and positive control samples were calculated in the first instance for all 
genes. geNORM analysis was carried out using qbasePLUS software (version 2.3; 
Biogazelle, Belgium) to determine stable reference genes (VIPAS39 and PRDM4), 
the geometric mean of which were used to normalize the data in subsequent 
experiments. 
Phospho-NFB p65 expression  
HCAEC were seeded at 200,000 cells/well in fibronectin coated 6-well plates. Cells 
were pre-treated for 30 min with the highest working concentrations of each serum 
profile (19 µM, 20 µM, 44 µM, reflecting 1 h, 6 h, and 24 h serum concentrations 
respectively) or 0.01% DMSO (vehicle control) prior to the addition of 10 ng/mL TNF-
α, and incubated for 15 min at 37oC, 5% CO2, in a humidified atmosphere. Cells 
were washed 3 x with PBS and lysed with NP-40 lysis buffer; total protein 
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concentrations were determined by BCA assay, and proteins were separated and 
probed by SDS-PAGE and Western blotting, respectively, as described previously by 
this group [20]. Primary antibody solution contained 0.1% PBS with 20% T20 
Blocking Buffer (Thermoscientific, UK), with rabbit polyclonal anti-NFB p65 
(Ser536) antibody (ab28856; Abcam, UK; 1:2000 dilution) and chicken polyclonal 
anti-GAPDH (AB2302; Millipore, UK; 1:15000 dilution) and secondary antibody 
solutions contained 0.1% PBS with 20% T20 Blocking Buffer and 0.1% SDS, with 
goat anti-rabbit (IRdye 800CW; Li-Cor, UK; 1:15000 dilution) and donkey-anti-
chicken (IRdye 680LT; Li-Cor, UK; 1:15000 dilution). Membranes were imaged and 
quantified by densitometry at 700 nm and 800 nm using Odyssey Infrared Imaging 
System and Odyssey Infrared Imaging System Application Software, respectively (Li-
Cor; version 3.0.21). 
Data analysis 
VCAM-1 and IL-6 protein (pg/mL) or mRNA (fold change) were recorded as the 
mean of two technical duplicates, and reported relative to the TNF-α positive control 
(containing TNF-α without DMSO) as the mean of three independent experiments. 
Phospho-NFB p65 expression (infrared density) data were normalized to GAPDH 
reference gene and data were presented graphically as a fold change of vehicle 
control (DMSO). Treatment effects were established by one-way analysis of variance 
(ANOVA) with post-hoc least significant difference (LSD) conducted using SPSS for 
Windows (version 22.0; IBM, New York, USA). Untreated controls were not included 
in the ANOVA for treatment effect but presented graphically, where Students t-test 
established difference relative to vehicle control (DMSO). All data represents the 
mean ± SD of three biological replicates (n=3). 
Results 
Effect of peak cyanidin-3-glucoside metabolite signatures on VCAM-1 protein 
expression.  
The effects of signatures of cyanidin-3-glucoside metabolites  (Figure 1) on TNF-α 
stimulated VCAM-1 secretion was explored at the mean concentrations observed 
clinically, as well as concentrations ten-fold lower and ten-fold higher (Table 1), in 
HUVEC and validated in HCAEC. No treatments were cytotoxic at any tested 
concentration as established utilizing the WST-1 cytotoxicity assay (Roche, United 
Kingdom). HUVEC-secreted VCAM-1 (Figure 2A) was reduced relative to the 
vehicle control in response to all treatments at all tested concentrations, with the 
maximal effects observed for 6 h and 24 h metabolite signatures (-65.12 ± 0.37% 
and -66.24 ± 2.88, respectively; p≤0.001) at cumulative concentrations of 20 µM and 
44 µM (respectively). The activity expressed in HCAEC was slightly less than that of 
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the HUVEC, however similarly, inhibition of HCAEC-secreted VCAM-1 (Figure 2B) 
was greatest for treatments reflecting the 6 h and 24 h metabolite signatures (-30.07 
± 11.41% and -27.84 ± 3.09%, respectively; p≤0.001). For both cell lines, even the 
profiles tested at concentrations 10-fold below the mean serum levels reported (0.19 
µM, 0.20 µM, 0.44 µM reflecting serum profiles at 1 h, 6 h, and 24 h, respectively) 
significantly reduced VCAM-1 secretion (p≤0.05).  
Effect of peak cyanidin-3-glucoside metabolite signatures on IL-6 protein 
expression.  
The effects of cyanidin-3-glucoside metabolite signatures (Figure 1) on TNF-α 
stimulated IL-6 secretion was explored at the mean concentration observed clinically 
(Table 1), as well as ten-fold lower and ten-fold higher concentrations in HUVEC and 
validated in HCAEC. HUVEC-secreted IL-6 (Figure 3A) was reduced relative to the 
vehicle control in response to all treatments, with the exception of the concentrations 
tested 10-fold below the mean serum levels (0.19 µM, 0.20 µM, 0.44 µM reflecting 
serum concentrations at 1 h, 6 h, and 24 h, respectively). Maximal effects on IL-6 
were observed in response to the three metabolite signatures (1 h, 6 h, 24 h) at 
cumulative concentrations of 2 µM, 20 µM, 44 µM, respectively (-36.63 ± 3.73%, -
31.26 ± 8.06%, -35.56 ± 0.70%; p≤0.001). Activity was not reduced in HCAEC in 
response to any treatment (p>0.05; Figure 3B). Maximal concentrations of each 
metabolite signature (19 µM, 20 µM, 44 µM), reflecting serum concentrations at 1 h, 
6 h, and 24 h, respectively) were taken forward to confirm their effect on VCAM-1 
and IL-6 mRNA in HCAEC. 
Effect of peak cyanidin-3-glucoside metabolite profiles on VCAM-1 and IL-6 
mRNA expression 
Peak metabolite signatures were used to determine whether TNF-α stimulated 
VCAM-1 and IL-6 protein secretion was reflected by mRNA expression in HCAEC 
(Figure 4). Here TNF-α stimulated VCAM-1 mRNA expression was reduced by 0.55 
± 0.25 fold, 0.49 ± 0.13 fold, and 0.36 ± 0.21 fold in response to 19 µM, 20 µM, 44 
µM concentrations as observed clinically at 1 h, 6 h, and 24 h (respectively), 
compared to the vehicle control (Figure 4A).  TNF-α stimulated IL-6 mRNA 
expression was reduced by 0.93 ± 0.10 fold, 1.18 ± 0.30 fold, and 1.01 ± 0.54 fold in 
response to 19 µM, 20 µM, 44 µM treatment profiles as observed clinically at 1 h, 6 
h, and 24 h, respectively (p≤0.05; Figure 4B). 
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Effect of peak cyanidin-3-glucoside metabolite signatures on phosphorylated 
NFB p65 expression. 
Peak metabolite signatures were further explored for their effect on TNF-α stimulated 
NFB transcription factor p65 in HCAEC (Figure 5), where there was no apparent 
activity beyond that of the vehicle control (p>0.05). 
Discussion 
The present study is the first to explore the activity of physiologically relevant 
signatures of anthocyanin metabolites. Here we utilized three unique treatments 
based on peak concentrations observed in serum post consumption (Figure 1) [8, 
11], with the aim of elucidating in vivo activity. Peak signatures of metabolites (Table 
1) displayed significant inhibitory effects on VCAM-1 protein secretion (Figure 2) at 
concentrations observed in vivo [11], suggesting physiologically achievable 
bioactivity. The greatest inhibition of VCAM-1 was observed in response to the 24 h 
metabolite signature, suggesting metabolites of lower intestinal microbial origin are 
responsible for fasting or chronic anti-inflammatory effects.  
Peak metabolite signatures appeared to have biological activity, despite the 
extremely low concentrations of their individual constitutes. Here responses were 
often greater then activities previously reported by our group for the same 
metabolites in isolation or in mixtures at equal molar concentrations [4, 5]. Previous 
studies have explored this concept of physiologically relevant concentrations of 
metabolite profiles by applying extracted serum/plasma to cell culture models. For 
example, Koga et al. found serum containing metabolites of (+)-catechin significantly 
reduced U937 adhesion to human aortic endothelial cells (HAEC) relative to the pure 
metabolites in isolation [21]. Other studies have used both extracted animal and 
human plasma in a similar manner [22-24], however the limitation of this study 
design is that plasma contains many bioactive constituents other than flavonoid 
metabolites, making it difficult to compare treatments to controls and eliminate 
confounders stemming from varying endogenous analytes. There is scope to 
validate the present findings using this model, however, these limitations still exist. 
The novelty of the present study is that the experiments can be appropriately 
controlled for vehicle, which allows a more direct exploration of mechanism of action. 
It could however be argued that this in itself is a limitation, as metabolites may act 
differentially in serum relative in cell culture media; Indeed, certain flavonoids have 
been shown to interact with serum albumin in in vitro or ex vivo conditions [25]. 
Furthermore, in utilizing average reported metabolite concentrations, compositions 
do not reflect individual participants’ blood profiles. Finally, the study design cannot 
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capture the impact of other blood metabolites/analytes escaping sample preparation 
and detection methodologies. 
The highest mean concentration of metabolites detected following the 500 mg bolus 
of 13C-labelled anthocyanins (equivalent to the consumption of approximately 100 g 
of blackberries [26]) was observed at 24 h post consumption and totaled 4.38 µM 
[11]. In this study, a high inter-individual variation in metabolism was observed. For 
example, the serum Cmax for hippuric acid was 1962 ± 1389 nM, indicating the mean 
concentration varies greatly between individuals and could be in excess of 3000 nM 
for a single metabolite. The present study sought to address this issue by utilizing 
treatment concentrations reflecting the lowest and highest concentrations reported 
between individuals (0.80 µM – 13.18 µM [8, 11]). As such, we used three metabolite 
concentrations, representing 10-fold higher and lower concentrations then the 
observed mean. Surprisingly, there was very little difference in the inhibition of 
VCAM-1 protein expression between the mean and ten-fold lower and higher 
concentrations of the metabolites. This suggests that either there is a threshold 
activity or that there is something unique about these mixtures of metabolites which, 
when combined, have some additive or synergistic activity. This outcome is 
important as these concentrations reflect dietary achievable levels [27]. As phenolic 
metabolites are common to a number of dietary flavonoids and food sources [28], it 
is possible that metabolite signature concentrations utilized in the present study 
could be exceeded following a habitual polyphenol-rich diet, given that consumption 
of polyphenols in Europe has been estimated between 744 mg/day - 1786 mg/day 
[29]. As effects were observed at the lowest concentrations in the present study 
(between 0.19 µM and 0.44 µM), even low levels of dietary polyphenol consumption 
would have beneficial effects on inflammatory status. 
Although peak metabolite profiles inhibited IL-6 secretion at 1 h, 6 h and 24 h in 
HUVEC, this was not reflected in HCAEC, though it is possible that effects were 
masked by the large variation between replicates. It is possible that the reduced 
stimulus (TNF-α) concentration (0.1 ng/mL in the present study relative to 10 ng/mL) 
increased variation as a result of low IL-6 induction, making it difficult to quantify 
significant activity. 
The effects of the treatments on VCAM-1 and IL-6 mRNA expression were 
investigated to determine whether these would reflect changes in protein expression. 
In our recent study [5], it was observed that only protocatechuic acid (PCA) inhibited 
VCAM-1 mRNA expression at the highest tested concentration, 100 µM. It is 
interesting that VCAM-1 and IL-6 mRNAs were reduced by half in response to the 3 
metabolite profiles which reflect cumulative total metabolite concentrations of only 19 
µM, 23 µM, and 44 µM, respectively. Given the low concentrations of metabolites in 
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the present treatment mixtures, it appears that certain metabolites are acting 
additively or synergistically, potentially through effecting multiple pathways 
simultaneously. Multiple pathways are indeed thought to be affected following 
anthocyanin metabolite treatment, for example, aortas of ApoE-deficient mice fed an 
anthocyanin-rich bilberry extract, demonstrated the modulation of 1261 genes which 
code for proteins involved in the regulation of cellular processes, including adhesion 
and inflammatory biomarker expression [14].  
NFB is a key transcription factor pathway in the TNF-α stimulated expression of 
adhesion molecules in endothelial cells [30]. In the present study, no effect was 
observed on the expression of phosphorylated p65, suggesting alternative 
mechanisms which influence adhesion molecule expression are at play, such as AP-
1 activity via p38 and JNK MAP kinase. A recent study of ours [5] as well as that of 
Krga et al. [31] also demonstrated no activity of flavonoid metabolites on  NFB.  
Data from the present study suggest that the metabolite profile with the maximum 
inflammatory effect was observed at 24 h post-consumption, suggesting fasting or 
chronic effects are possible. Conversely, improvements in flow-mediated dilation 
(FMD) and blood pressure in response to feeding anthocyanins are most often 
observed acutely, between 1 h and 6 h post-consumption (maximum response at 2 
h) [32]. In the study of Rodriguez-Mateos et al. [32], following the consumption of a 
drink containing blueberry anthocyanins, benzoic and vanillic acids positively 
correlated with FMD at 1–2 h, whereas hippuric, hydroxyhippuric, and homovanillic 
acids correlated with the FMD at 6 h. These data suggests an acute-phase 
modulatory vascular response of phenol metabolites. Based on these findings and 
those of the present study it is possible that sudden vascular responses are 
mediated by very low levels of parent flavonoids and their rapid degradation 
products, which are succeeded by a delayed anti-inflammatory response, mediated 
by products of lower intestinal bacterial catabolism and hepatic phase II conjugation. 
This ultimately suggests a dual mechanistic activity of flavonoids. This hypothesis 
requires conformation in randomized-control trials designed having inflammation as 
a primary endpoint and utilizing populations both responsive to inflammatory and 
vascular intervention following dietary manipulation (i.e., neither completely healthy 
nor chronically unhealthy), as flavonoids are likely to be effective as a preventative 
strategy rather than a pharmacological therapy.   
In conclusion, the present study identified that signatures of anthocyanin metabolites 
identified post consumption of dietary achievable levels of anthocyanins, have 
inhibitory effects on inflammatory protein secretion. Further work is required to 
elucidate the multiple mechanisms potentially at play, ultimately informing our 
understanding of how anthocyanins and other flavonoids impact health.  
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Figure 1. Serum pharmacokinetic signatures of C3G and its metabolites in 
humans after the consumption of 500 mg 13C5-C3G in eight healthy male 
participants. Data represent mean concentration of specified metabolites from 8 
participants. Peak signatures (at 1 h, 6 h, and 24 h) are indicated by the dashed-line 
boxes. “/” indicates isomers quantified together. Common name (chemical name): 4-
hydroxybenzyldehyde (4-hydroxybenzoicaldehyde); Benzoic acid-4-glucuronide 
(benzoic acid-4-O-glucuronide); Cyanidin-3-glucoside (2-(3,4-dihydroxyphenyl)-5,7-
dihydroxy-3-chromeniumyl-β-D-glucopyranoside); Ferulic acid (4-hydroxy-3-
methoxycinnamic acid); Hippuric acid (N-benzoylglycine); Isovanillic acid (3-hydroxy-
4-methoxybenzoic acid); Isovanillic acid-3-glucuronide (4-methoxybenzoic acid-3-O-
glucuronide); Isovanillic acid-3-sulfate (4-methoxybenzoic acid-3-sulfate); 
Phloroglucinaldehyde (2,4,6-trihydroxybenzaldehyde); Protocatechuic acid (3,4-
dihydroxybenzoic acid); Protocatechuic acid-3-sulfate (4-hydroxybenzoic acid-3-
sulfate); Protocatechuic acid-4-glucuronide (3-hydroxybenzoic acid-4-O-
glucuronide); Protocatechuic acid-4-sulfate (3-hydroxybenzoic acid-4-sulfate); 
Vanillic acid (3-methoxy-4-hydroxybenzoic acid); Vanillic acid-4-glucuronide (3-
methoxybenzoic acid-4-O-glucuronide); Vanillic acid-4-sulfate (3-methoxybenzoic 
acid-4-sulfate). Adapted from de Ferrars et al. [11]. 
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Figure 2. Effect of peak metabolite signatures on TNF-α stimulated VCAM-1 
secretion by A) HUVEC, B) HCAEC. Cells were treated with 3 concentrations of 3 
serum metabolite profiles (representing ten-fold lower and ten-fold higher 
concentrations than the mean concentrations observed by Czank et al. [8]; Table 1) 
prior to the addition of 10 ng/mL or 0.1 ng/mL TNF-α for 24 h. Data were normalized 
to a TNF-α control (no DMSO) and columns represent the mean ± SD, n = 3 
biological replicates. Labelled means without a common letter differ, p≤ 0.05 
(ANOVA with post hoc LSD). *Different from DMSO, p≤ 0.05 (t-test). Abbreviations: 
HUVEC, human umbilical vein endothelial cells; TNF-α, tumor necrosis factor-α; 
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Figure 3. Effect of peak metabolite signatures on TNF-α stimulated IL-6 
secretion by A) HUVEC, B) HCAEC. Cells were treated with 3 concentrations of 3 
serum metabolite profiles (representing ten-fold lower and ten-fold higher 
concentrations than the mean concentrations observed by Czank et al. [8]; Table 1) 
prior to the addition of 10 ng/mL or 0.1 ng/mL TNF-α for 24 h. Data were normalized 
to a TNF-α control (no DMSO) and columns represent the mean ± SD, n = 3 
biological replicates. Labelled means without a common letter differ, p≤ 0.05 
(ANOVA with post hoc LSD). *Different from DMSO, p≤ 0.05 (t-test). Abbreviations: 
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Figure 4. Effect of peak metabolite signatures on TNF-α stimulated VCAM-1 
and IL-6 mRNA expression in HCAEC A) VCAM-1, B) IL-6.  Cells were treated 
with the highest concentration signature metabolites (19 µM, 20 µM, 44 µM reflecting 
1 h, 6 h, and 24 h serum profiles respectively; Czank et al. [8]) and stimulated with 
0.1 ng/mL TNF-α for 4 h. Amplification values were normalized to the geometric 
mean of two stable reference genes, VIPAS39 and PRDM4. Data where normalized 
to a TNF-α control (no DMSO) and columns represent the mean ± SD, n = 3 
biological replicates. Labelled means without a common letter differ significantly, p≤ 
0.05 (ANOVA with post hoc LSD). *Different from DMSO, p≤ 0.05 (t-test). 
Abbreviations: HCAEC, human coronary artery endothelial cells; TNF-α, tumor 
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Figure 5. Effect of peak metabolite signatures on TNF-α stimulated phosphor-
NFB p65 expression in HCAEC. Cells were treated with the highest concentration 
signature metabolites (19 µM, 20 µM, 44 µM reflecting 1 h, 6 h, and 24 h serum 
profiles respectively; Czank et al. [8]), and stimulated with 10 ng/mL TNF-α  for 15 
min. Data were normalized to the vehicle control (DMSO) and columns represent the 
mean ± SD, n = 3 biological replicates. Blots are representative of one of three 
replicates. Density values were normalized to reference protein, GAPDH. Labelled 
means without a common letter differ significantly, p≤0.05 (ANOVA with post hoc 
LSD). Comparisons of untreated cells to vehicle control (DMSO) were established 
via Student’s t-test, *p≤ 0.05. Abbreviations: HCAEC, human coronary artery 
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Final  profile concentration (nM) 
1 h profile 6 h profile 24 h profile 
4-Hydroxybenzyldehyde 1 10 100 1 10 100 1 10 100 
Benzoic acid-4-glucuronide  1 10 100 4 40 400 4 40 400 
Cyanidin-3-glucoside  5 50 500 0 0 0 0 0 0 
Ferulic acid 29 290 2900 21 210 2100 59 590 5900 
Hippuric acid  7 70 700 23 230 2300 194 1940 19400 
Isovanillic acid 12 120 1200 0 0 0 0 0 0 
Isovanillic acid-3-glucuronide   1 10 100 2 20 200 0 0 0 
Isovanillic acid-3-sulfate  0 0 0 0 0 0 17 170 1700 
Phloroglucinaldehyde 3 30 300 55 550 5500 5 50 500 
Protocatechuic acid 4 40 400 8 80 800 1 10 100 
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Protocatechuic acid-3-sulfate  7 70 700 2 20 200 2 20 200 
Protocatechuic acid-4-glucuronide  2 20 200 3 30 300 0 0 0 
Protocatechuic acid-4-sulfate  7 70 700 2 20 200 2 20 200 
Vanillic acid  110 1100 11000 80 800 8000 136 1360 13600 
Vanillic acid-4-O-glucuronide  1 10 100 2 20 200 0 0 0 
Vanillic acid-4-sulfate  0 0 0 0 0 0 17 170 1700 
Total 190 1900 19000 203 2030 20300 438 4380 43800 
Table 1. Serum profile constituents and concentrations 
Common name (chemical name): 4-hydroxybenzyldehyde (4-hydroxybenzoicaldehyde); Benzoic acid-4-glucuronide (benzoic acid-4-
O-glucuronide); Cyanidin-3-glucoside (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromeniumyl-β-D-glucopyranoside); Ferulic acid (4-
hydroxy-3-methoxycinnamic acid); Hippuric acid (N-benzoylglycine); Isovanillic acid (3-hydroxy-4-methoxybenzoic acid); Isovanillic 
acid-3-glucuronide (4-methoxybenzoic acid-3-O-glucuronide); Isovanillic acid-3-sulfate (4-methoxybenzoic acid-3-sulfate); 
Phloroglucinaldehyde (2,4,6-trihydroxybenzaldehyde); Protocatechuic acid (3,4-dihydroxybenzoic acid); Protocatechuic acid-3-sulfate 
(4-hydroxybenzoic acid-3-sulfate); Protocatechuic acid-4-glucuronide (3-hydroxybenzoic acid-4-O-glucuronide); Protocatechuic acid-
4-sulfate (3-hydroxybenzoic acid-4-sulfate); Vanillic acid (3-methoxy-4-hydroxybenzoic acid); Vanillic acid-4-glucuronide (3-
methoxybenzoic acid-4-O-glucuronide); Vanillic acid-4-sulfate (3-methoxybenzoic acid-4-sulfate). 
